TSL.L Regulatory News (TSL)

29 Jun 2007 16:00

Tissue Science Laboratories PLC29 June 2007 29 June 2007 Tissue Science Laboratories PLC ("TSL" or "the Company") Total Voting Rights and Share Capital In conformity with Financial Services Authority's Disclosure and TransparencyRules, Tissue Science Laboratories plc is required to notify the market of thefollowing: Tissue Science Laboratories' issued share capital consists of 34,609,157ordinary shares with a nominal value of 10 pence each, with voting rights.Tissue Science Laboratories plc does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights is 34,609,157. The above figure of 34,609,157 shares may be used by shareholders as thedenominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, TissueScience Laboratories under the Financial Service Authority's Disclosure andTransparency Rules. -Ends- Enquiries:TSL plc Tel: 01252 333 002David Jennings, Finance Director Nomura Code Securities Tel: 0207 776 1200Clare Terlouw Hogarth Partnership Limited Tel: 020 7645 3965Melanie Toyne Sewell Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head & face-US and Canada). Further variations of the sheetand injectable forms of Permacol(R) are being developed. This information is provided by RNS The company news service from the London Stock Exchange